<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="223">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612573</url>
  </required_header>
  <id_info>
    <org_study_id>PR-07907</org_study_id>
    <secondary_id>WC2055</secondary_id>
    <nct_id>NCT00612573</nct_id>
  </id_info>
  <brief_title>Treatment of Moderate to Severe Facial Acne Vulgaris</brief_title>
  <official_title>Phase 2 Study Randomized, Double-blind Study to Evaluate the Safety and Efficacy of 3 Doses of Doxycycline as Compared to Placebo in the Treatment of Moderate to Severe Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Warner Chilcott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Warner Chilcott</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the
      safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the
      Investigator's Global Assessment (IGA) score and the absolute change from baseline in
      inflammatory lesion count in patients with moderate to severe facial acne vulgaris.
      Additionally, the absolute change from baseline in non-inflammatory and total lesions of the
      active study medication to placebo will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage Patients With Successful Outcome Investigator's Global Assessment (IGA) Score at Week 12, Intent to Treat (ITT) Population</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>IGA: 0/clear (clear skin no lesions, inflammatory or non-inflammatory), 1/almost clear (rare non-inflammatory lesion w/no more than 1 small inflammatory lesion), 2/mild (some non-inflammatory lesions with no more than a few inflammatory lesions, papules/pustules only, no nodular lesions), 3/moderate (up to many non-inflammatory lesions, some inflammatory lesions, no more than 1 small nodular lesion), 4/severe (many non-inflammatory &amp; inflammatory lesions, no more than a few nodular lesions. Lower score improvement in score. Success=IGA decrease of at least 2 grades from baseline score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute Change in Inflammatory Lesion Count From Baseline to Week 12, ITT Population</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change derived as Baseline evaluation minus the Week 12 evaluation.  Thus a positive change reflects a reduction in lesion count.  Inflammatory Lesion Count includes nodules, papules and pustules.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline to Week 12 in NonInflammatory Lesion Count, ITT Population</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Noninflammatory Lesion Count includes open and closed comedones.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline to Week 12 in Total Lesion Count, ITT Population</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Total Lesion Count is the sum of inflammatory and noninflammatory lesions.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">257</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Doxycyline 0.6 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline dosed at 40 mg/day to subjects of appropriate weights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline 1.2 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline dosed at 80 mg/day to subjects of appropriate weights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline 2.4 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxycycline dosed at 160 mg/day to subjects of appropriate weights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 0.6 mg/kg/day</intervention_name>
    <description>doxycycline 40 mg/day, oral, 12 weeks</description>
    <arm_group_label>Doxycyline 0.6 mg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 1.2 mg/kg/day</intervention_name>
    <description>doxycycline 80 mg/day, 12 weeks</description>
    <arm_group_label>Doxycycline 1.2 mg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 2.4 mg/kg/day</intervention_name>
    <description>doxycycline 160 mg/day, 12 weeks</description>
    <arm_group_label>Doxycycline 2.4 mg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be between 12 and 45 years of age.

          -  Has a diagnosis of moderate to severe facial acne vulgaris with no more than two
             nodules on the face

        Exclusion Criteria:

          -  Is allergic to tetracycline-class antibiotics or to any ingredient in the study
             medication.

          -  Has a history of pseudomembranous colitis or antibiotic-associated colitis.

          -  Has a history of hepatitis or liver damage or renal impairment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angelo Secci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Warner Chilcott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106-5239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Broomall</city>
        <state>Pennsylvania</state>
        <zip>19008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Fort Washington</city>
        <state>Pennsylvania</state>
        <zip>19034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warner Chilcott Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 15, 2013</lastchanged_date>
  <firstreceived_date>January 25, 2008</firstreceived_date>
  <firstreceived_results_date>February 14, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
